Local breast cancer recurrence is when the cancer has reoccurred close to or in the same place the first tumor was found within the breast. If you were treated with lumpectomy and radiation for your first occurrence, the breast tissue cannot be treated with radiation again. In that case, the standard of care for surgical treatment is mastectomy.If radiation was not part of your original treatment when lumpectomy was performed, then another lumpectomy followed by radiation may be recommended. If there is not adequate breast volume remaining for lumpectomy, mastectomy may be recommended. Depending on the medical oncologist’s evaluation, which is based on the prognostic factors of the tumor, he or she may recommend chemotherapy and/or hormonal therapy.Distant breast cancer recurrence is when the cancer has spread to another organ within the body. Breast cancer that has spread—also called metastatic breast cancer—is no longer curable and needs to be managed as a chronic disease. There are various treatment options to control the cancer and stop its progression, prolonging a patient’s life and improving quality of life. These treatments may include:Chemotherapy, Radiation therapy, Hormonal therapy, Biologic targeted therapy, Clinical trials.
Each year, approximately 70 thousand men and women age 15 to 39 are diagnosed with cancer in the belgium. Breast cancer is the most common cancer for women in this age group. Women ages 15 to 34 and 35 to 54 die more frequently from breast cancer than any other cancer.the belgium Cancer Society projected 230,480 new cases of invasie breast cancer among belgium women annually, as well as an estimated 57,650 additional cases of in situ breast cancer. It is estimated that 13,110 cases of breast cancer will be in women under age 404 and approximately 26,275 women will be under 45 years of age.Every year, nearly 1,200 women under age 40 die from breast cancer.Randomized and observational studies reported that HRT increases the risk of VTE (2 to 3 fold) (level 1, 2 of evidence). This means that in a cohort of 1000 women using HRT, an additional 2 cases occur per year of use on a typical baseline risk of 1 per 1000 woman-years. Standard ET doses were associated with a rare, but significant increase in VTE (WHI) (0.8 excess/ 1000 women-year). Major identified risk factors are age, overweight, sedentarity and thrombophilia. The risk is highest during the first year of use. This risk may be lower using low oral doses of H(R)T or using H(R)T regimens with transdermal/percutaneous estrogens (level 2 of evidence).Today’s stage IV is very different from that 15-20 years ago: progress in imaging.Median survival times: 42 - 79 months 5 y actuarial survival: 35 - 89% 10 y actuarial survival: 8 - 60%